InvestorsHub Logo
Followers 52
Posts 5313
Boards Moderated 0
Alias Born 09/16/2013

Re: None

Monday, 11/19/2018 9:46:37 AM

Monday, November 19, 2018 9:46:37 AM

Post# of 686787
New PR: https://www.nwbio.com/press-releases/

Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma

Presented at Society for Neuro-Oncology Conference Data Continuing to Mature, Particularly Regarding Long Tail of Survival Curve BETHESDA, Md., November 19, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News